Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Anal...
13 Maio 2021 - 9:30AM
Daxor Corporation (NYSE MKT: DXR), the global leader in blood
volume measurement technology, today announced a Q1 2021 increase
in revenue of 61% in its operating division on a year-over-year
basis. In addition, the sales team has recorded the opening of five
new customer accounts utilizing BVA and reports a growing pipeline
of additional acquisitions of Daxor’s BVA-100 Blood Volume Analyzer
slated for Q3 2021 at major medical centers across the U.S.
“Sales are accelerating as the COVID
restrictions are relaxed at hospital centers, allowing our teams to
resume on-site visits with customers, accelerating onboarding and
the acquisition of our systems," said Jean Oertel, Vice President
of Commercialization and Customer Experience. "We expect that we
will have access to over 70% of our client hospitals by the end of
Q2 2021. We anticipate that the ease of educating clinicians and
providing hands-on training will further accelerate business in the
ensuing quarters to come.”
"As our commercial uptake is increasing, we have
added additional resources to our sales and marketing team, having
hired and trained three additional product representatives to our
in-house team as we also work to increase access through
third-party distribution agreements as well,” said Michael
Feldschuh, President and CEO of Daxor Corporation.
Jonathan Feldschuh, Chief Scientific Officer of
Daxor noted, “The increase in sales and sales team members fit well
with our planned next-generation analyzer product development
schedule, which includes production of both nuclear and novel
fluorescing-based point-of-care testing devices over the next year.
Our next-generation system promises to be even faster, easier, and
expand use of our test into more clinical settings for more
indications, which we anticipate will be well-received by our
expanding customer base."
Daxor manufactures the BVA-100 blood test system
which provides a simple, inexpensive, objective measurement of
volume status and composition providing clinicians with actionable
results to optimize fluid management and improve patient outcomes
while driving substantial cost savings throughout the healthcare
system.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. The BVA technology enhances hospital performance metrics in
a broad range of surgical and medical conditions, including heart
failure and critical care, by informing treatment strategies,
resulting in significantly improved multiple measures of patient
outcomes. Daxor's mission is to advance healthcare by enabling
optimal fluid management with blood volume analysis. Daxor’s vision
is optimal blood volume for all. For more information, please visit
our website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024